| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328363 | Acta Haematologica Polonica | 2013 | 4 Pages |
Abstract
We present a case of a 64-year-old man who was treated with rituximab after second progression of HCL. In March 2011, rituximab was given at a dose of 375Â mg/m2 i.v. once a week for eight weeks, with result of achievement of PR. During the last hospitalization in March 2013 the persistence of PR was confirmed.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Klaudia GrÄ
dzka, Kamila Kruczkowska-Tarantowicz, Marzenna B. Klimiuk, Janusz KÅoczko,